<SEC-DOCUMENT>0001171843-25-003354.txt : 20250521
<SEC-HEADER>0001171843-25-003354.hdr.sgml : 20250521
<ACCEPTANCE-DATETIME>20250520185046
ACCESSION NUMBER:		0001171843-25-003354
CONFORMED SUBMISSION TYPE:	424B2
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250521
DATE AS OF CHANGE:		20250520

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PORTAGE BIOTECH INC.
		CENTRAL INDEX KEY:			0001095435
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			D8
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		424B2
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-286961
		FILM NUMBER:		25970465

	BUSINESS ADDRESS:	
		STREET 1:		CLARENCE THOMAS BUILDING
		STREET 2:		P.O. BOX 4649, ROAD TOWN
		CITY:			TORTOLA
		STATE:			D8
		ZIP:			VG1110
		BUSINESS PHONE:		416-737-7600

	MAIL ADDRESS:	
		STREET 1:		CLARENCE THOMAS BUILDING
		STREET 2:		P.O. BOX 4649, ROAD TOWN
		CITY:			TORTOLA
		STATE:			D8
		ZIP:			VG1110

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BONTAN CORP INC
		DATE OF NAME CHANGE:	20030421

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DEALCHECK COM INC
		DATE OF NAME CHANGE:	19990921
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B2
<SEQUENCE>1
<FILENAME>f424b2_052025.htm
<DESCRIPTION>424B2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0">Filed Pursuant to rule 424(b)(2)</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: right">Registration Statement No. 333-286961</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">PROSPECTUS</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">$40,000,000</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>PORTAGE BIOTECH INC.</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Ordinary Shares</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Warrants</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">Units</P>

<P STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">This prospectus relates to ordinary shares, warrants
and units that we may sell from time to time in one or more offerings up to a total public offering price of $40,000,000 on terms to be
determined at the time of sale. This prospectus only provides a general description of the offerings of these types of our securities.</P>


<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Each time we offer and sell securities pursuant to
this prospectus, we will provide a supplement to this prospectus that contains specific information about such offering and the terms
of the securities. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings.
The prospectus supplement and any related free writing prospectus may add, update or change information contained in this prospectus.
You should read carefully this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as the
documents incorporated or deemed to be incorporated by reference, before you invest in any of our securities. This prospectus may not
be used to offer and sell securities unless accompanied by a prospectus supplement for the specific of our securities.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">We may offer and sell the securities from time to
time at fixed prices, at prevailing market prices or at negotiated prices, pursuant to one or more of the following methods: through
agents, to or through underwriters, to or through broker-dealers, in &ldquo;at the market offerings&rdquo; within the meaning of Rule
415(a)(4) of the Securities Act, directly to a limited number of purchasers or to a single purchaser, or through a combination of any
of these methods. If any underwriters, dealers or agents are involved in the sale of any securities with respect to which this prospectus
is being delivered, the names of such underwriters, dealers or agents and any applicable commissions or discounts will be set forth in
a prospectus supplement. The offering price of such securities and the net proceeds we expect to receive from such sale will also be
set forth in a prospectus supplement. See the section entitled &ldquo;Plan of Distribution&rdquo; in this prospectus for a more complete
description of the ways in which the securities may be offered and sold.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Our ordinary shares are traded on the NASDAQ Stock
Market under the symbol &ldquo;PRTG.&rdquo; On May 14, 2025, the closing price of an ordinary share on NASDAQ was $7.68.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><B>Investing in our securities involves certain risks.
investors should be aware that there are various other risks relating to the securities, the issuer and its subsidiaries, their business
and their jurisdictions of operations which investors should familiarize themselves with before making an investment in the securities.
See the section &ldquo;Risk Factors&rdquo; of this prospectus and in any prospectus supplement before you make your investment decision.</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">The date of this prospectus is May 14, 2025.</P>

<P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>Table of Contents</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="background-color: white">
    <TD STYLE="width: 95%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 5%"><B>Page</B></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_001">ABOUT THIS PROSPECTUS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_001">1</A></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_002">WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_002">1</A></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_003">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_003">2</A></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_004">PROSPECTUS SUMMARY</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_004">4</A></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_005">RISK FACTORS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_005">4</A></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_006">THE BUSINESS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_006">5</A></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_007">USE OF PROCEEDS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_007">8</A></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_008">DESCRIPTION OF ORDINARY SHARES WE MAY OFFER </A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_008">8</A></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_009">DESCRIPTION OF WARRANTS WE MAY OFFER </A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_009">19</A></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_011">DESCRIPTION OF UNITS WE MAY OFFER</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_011">20</A></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_012">PLAN OF DISTRIBUTION</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_012">20</A></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_013">CERTAIN UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_013">23</A></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_016">TRANSFER AGENT</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_016">24</A></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_017">LEGAL MATTERS</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_017">24</A></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_018">EXPERTS </A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_018">24</A></TD></TR>
  <TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD><A HREF="#a_019">ENFORCEABILITY OF CIVIL LIABILITIES</A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_019">25</A></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><B>We have not authorized any broker-dealer, salesperson
or other person to give any information or to make any representation other than those contained or incorporated by reference in this
prospectus and the accompanying supplement to this prospectus. You must not rely upon any information or representation not contained
or incorporated by reference in this prospectus or the accompanying prospectus supplement. This prospectus and the accompanying supplement
to this prospectus do not constitute an offer to sell or the solicitation of an offer to buy securities, nor do this prospectus and the
accompanying supplement to this prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction
to any person to whom it is unlawful to make such offer or solicitation. The information contained in this prospectus and the accompanying
prospectus supplement speaks only as of their respective dates and may not reflect subsequent changes in our business, financial condition,
results of operations and prospects even though this prospectus and any accompanying prospectus supplement is delivered or securities
are sold on a later date.</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><B>We are not making an offer to sell the securities
or soliciting an offer to buy the securities in any jurisdiction where the offer or sale is not permitted.</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B><A NAME="a_001"></A>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">You should read this prospectus and any prospectus
supplement together with the additional information described under the heading &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">In this prospectus, unless otherwise indicated or unless
the context otherwise requires:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 1in">&ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our company,&rdquo;
&ldquo;the company,&rdquo; &ldquo;our&rdquo; or &ldquo;Portage&rdquo; refers to Portage Biotech Inc., a British Virgin Islands company,
its predecessor entities and its wholly and partially owned subsidiaries;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 1in">all references to &ldquo;$,&rdquo; &ldquo;dollars&rdquo;
or &ldquo;U.S. dollars&rdquo; refer to the legal currency of the United States; all references to &ldquo;&pound;&rdquo; and &ldquo;pounds
sterling&rdquo; refer to the legal currency of the United Kingdom; all references to &ldquo;&euro;&rdquo; or &ldquo;euro&rdquo; refer
to the official currency of the European Union and the currency that is used in certain of its member states; and</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 1in">&ldquo;shares&rdquo; or &ldquo;ordinary shares&rdquo;
refers to the authorized ordinary shares of Portage Biotech Inc., with no par value.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">This prospectus is part of a shelf registration statement
that we filed with the U.S. Securities and Exchange Commission, or the SEC, using a &ldquo;shelf&rdquo; registration process. By using
a shelf registration statement, we may sell our ordinary shares, warrants to acquire ordinary shares, or units, and units comprising a
combination of any of the foregoing from time to time, in one or more offerings, on a continuous or delayed basis. This prospectus only
provides you with a summary description of these securities. Each time we sell the securities, we will provide a supplement to this prospectus
that contains specific information about the securities being offered and the specific terms of that offering. The supplement may also
add, update or change information contained in this prospectus. If there is any inconsistency between the information in this prospectus
and any prospectus supplement, you should rely on the prospectus supplement. Before purchasing any of the securities, you should carefully
read both this prospectus and any supplement, together with the additional information described under the heading &ldquo;Where You Can
Find More Information.&rdquo;</P>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><A NAME="a_002"></A>WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">We file annual and special reports, proxy statements
and other information with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;). You can inspect and copy these reports, proxy
statements and other information at the SEC&rsquo;s Public Reference Room at 100 F Street, N.E., Washington, D. C. 20549. Please call
the SEC at 1-800-SEC-0330 for further information on the Public Reference Room. The SEC also maintains a web site that contains reports,
proxy and information statements and other information regarding issuers (www.sec.gov). Our web site is located at www.portagebiotech.com.
The information contained on our web site is not part of this prospectus.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">This prospectus &ldquo;incorporates by reference&rdquo;
certain information that we have filed with the SEC under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;).
This means we are disclosing important information to you by referring you to those documents. We incorporate by reference the documents
listed below and any future filings made by us with the SEC under Sections 13(a), 13(c) or 15(d) of the Exchange Act until the offering
is terminated:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%">
    <P STYLE="font-size: 10pt; text-align: justify; text-indent: -9.35pt; margin: 0pt 0 0pt 36.7pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>
    our Annual Report on Form 20-F for the fiscal year ended March 31, 2024, filed with the SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1095435/000117184324004800/f20f_081224.htm">August 14, 2024</A>;</P>
    <P STYLE="font: 10pt Symbol; text-align: justify; text-indent: -9pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font-size: 10pt; text-align: justify; text-indent: -9pt; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>
    our Reports on Form 6-K filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184324001997/f6k_041224.htm">April
    12, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184324002370/f6k_043024.htm">May 1, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184324004725/f6k_081224.htm">August
    13, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184324004823/f6k_081524.htm">August 15, 2024</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1095435/000117184324004936/f6k_082624.htm">August
    27, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184324005042/f6k_090324.htm">September 4, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184324005512/f6k_100424.htm">October
    4, 2024</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1095435/000117184324006599/f6k_112624.htm">November 26,
    2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184324006770/f6k_120524.htm">December 5, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184324006910/f6k_121224.htm">December
    12, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184324006941/f6k_121324.htm">December 13, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184324006976/f6k_121724.htm">December
    17, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184325000032/f6k_010625.htm">January 6, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184325000535/f6k_012925.htm">January
    30, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184325000769/f6k_022525.htm">February 12, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184325001423/f6k_031225.htm">March
    12, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184325001459/f6k_031325.htm">March 13, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184325001781/f6k_032725.htm">March
    27, 2025</A> and <A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184325002525/f6k_042525.htm">April 28, 2025</A>;
    and</P>
    <P STYLE="font: 10pt Symbol; text-align: justify; text-indent: -9pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font-size: 10pt; text-align: justify; text-indent: -9pt; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>
    with respect to each offering of the securities under this prospectus, all our subsequent annual reports on Form 20-F and any report on
    Form 6-K that indicates that it is being incorporated by reference, in each case, that we file or furnish with the SEC on or after the
    date on which the registration statement is first filed with the SEC and until the termination or completion of the offering under this
    prospectus; and</P>
    <P STYLE="font-size: 10pt; text-align: justify; text-indent: -9pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.5in; text-align: justify; text-indent: -9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT> The description of our ordinary shares contained in the Registration Statement on Form 8-A, filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000106299321001661/form8a12b.htm">February 18, 2021</A>, including any further amendment or report filed hereafter for the purpose of updating such description. </TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">As a foreign private issuer, we are exempt from the
rules under Section 14 of the Exchange Act prescribing the furnishing and content of proxy statements and our officers, directors and
principal shareholders are exempt from the reporting and other provisions in Section 16 of the Exchange Act.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">We will provide, upon written or oral request, without
charge to you, including any beneficial owner of our ordinary shares to whom this prospectus is delivered, a copy of any or all of the
documents incorporated herein by reference other than the exhibits to those documents, unless those exhibits are specifically incorporated
by reference into the information that this prospectus incorporates. You should direct a request for copies in writing to us at Attention:
Chief Financial Officer, c/o Portage Biotech Inc., 1111B S Governors Ave Ste 25907, Dover, Delaware 19904.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">You should rely only on the information that we incorporate
by reference or provide in this prospectus or any supplement or amendment hereto. We have not authorized anyone to provide you with different
information. We are not making any offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should
not assume that the information contained or incorporated by reference in this prospectus or any supplement or amendment hereto is accurate
as of any date other than the date of the document containing the information.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><A NAME="a_003"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Certain information set forth in this prospectus or
incorporated by reference in this prospectus may contain forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;), that are intended to be covered by the &ldquo;safe harbor&rdquo; created by those sections. Forward-looking statements, which
are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of
forward-looking terms such as &ldquo;believe,&rdquo; &ldquo;expect,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo;
&ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;seek,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;estimate,&rdquo; &ldquo;goal,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;project&rdquo; or other comparable terms. Forward-looking statements involve inherent risks and uncertainties
which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including
those risks and uncertainties included in this prospectus under the caption &ldquo;Risk Factors,&rdquo; and those risks and uncertainties
described in the documents incorporated by reference into this prospectus. We urge you to consider those risks and uncertainties in evaluating
our forward-looking statements. All subsequent written and oral forward-looking statements attributable to us or to persons acting on
our behalf are expressly qualified in their entirety by the applicable cautionary statements. We further caution readers not to place
undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal
securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement
contained herein or in the accompanying prospectus (or elsewhere) to reflect any change in our expectations with regard thereto or any
change in events, conditions or circumstances on which any such statement is based.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Risks and uncertainties that could cause actual results
to vary from expected results expressed in our forward-looking statements include, but are not limited to:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.55in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -9.35pt; margin: 0pt 0 0pt 36.7pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>
our need for financing and our estimates regarding our capital requirements and future revenues and profitability;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -9pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-align: justify; text-indent: -9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT> our plans and ability to develop and commercialize product candidates and the timing of these development programs;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-align: justify; text-indent: -9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT> clinical development
of our product candidates, including the timing for availability and release of results of current and future clinical trials; &nbsp;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-align: justify; text-indent: -9pt"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-align: justify; text-indent: -9pt"><FONT STYLE="font-family: Symbol">&middot;</FONT>
our expectations regarding regulatory communications, submissions or approvals;</P>

<P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font-size: 10pt; text-align: justify; text-indent: -9pt; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>
the potential functionality, capabilities, benefits and risks of our product candidates as compared to others;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -9pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -9pt; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>
our maintenance and establishment of intellectual property rights in our product candidates;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -9pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -9pt; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>
our estimates of the size of the potential markets for our product candidates; and</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -9pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -9pt; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>
our selection and licensing of product candidates.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The risks and uncertainties set forth above are not
exhaustive and additional factors, including those identified in this prospectus under the heading &ldquo;Risk Factors,&rdquo; and factors
described elsewhere in this prospectus and in other filings we periodically make with the SEC, including the other risks and uncertainties
identified in Item 3.D. Risk Factors in our Annual Report on Form 20-F for the year ended March 31, 2024, could adversely affect our business
and financial performance. Therefore, you should not rely unduly on any of these forward-looking statements. Forward-looking statements
contained in this prospectus speak as of the date hereof and we do not undertake any obligation to update or revise any of these forward-looking
statements, whether as a result of new information, future events and developments or otherwise, except as required by law.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B><A NAME="a_004"></A>PROSPECTUS SUMMARY</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">This prospectus is part of a registration statement
on Form F-3 that we filed with the SEC utilizing a &ldquo;shelf&rdquo; registration process. Under this shelf process, we may from time
to time, sell any combination of securities described in this prospectus in one or more offerings. This prospectus provides you with a
general description of the securities we may offer. Each time we sell securities, we will provide a prospectus supplement that will contain
specific information about the terms of the securities being offered and risk factors specific to that offering.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">We may add or modify in a prospectus supplement any
of the information contained in this prospectus or in the documents that we have incorporated into this prospectus by reference. If there
is any inconsistency between the information in this prospectus and a prospectus supplement, you should rely on the information in that
prospectus supplement. You should read both this prospectus and any applicable prospectus supplement together with additional information
described above under the heading &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">When acquiring any securities discussed in this prospectus,
you should rely on the information provided in this prospectus and the prospectus supplement, including the information incorporated by
reference. Neither we, nor any underwriters, dealers or agents, have authorized anyone to provide you with different information. We are
not offering the securities in any state where such an offer is prohibited. You should not assume that the information in this prospectus,
any prospectus supplement, or any document incorporated by reference, is truthful or complete at any date other than the date mentioned
on the cover page of those documents. You should also carefully review the section entitled &ldquo;Risk Factors,&rdquo; which highlights
certain risks associated with an investment in our securities, to determine whether an investment in our securities is appropriate for
you.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><A NAME="a_005"></A>RISK FACTORS</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Investing in our securities involves a high degree
of risk. You should carefully consider risk factors described in our Annual Report on Form 20-F for our fiscal year ended March 31, 2024
and those contained in our other filings with the SEC, which are incorporated by reference in this prospectus, and any accompanying prospectus
supplement and all other information contained in this prospectus and in any supplementary prospectus relating to the offering of any
of our securities before purchasing any of our securities. Some statements in this prospectus, constitute forward-looking statements.
Please refer to the section entitled &ldquo;Forward-Looking Statements.&rdquo;</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>The prospectus supplement applicable to each type
or series of securities we offer may contain a discussion of risks applicable to the particular types of securities that we are offering
under that prospectus supplement. Prior to making a decision about investing in our securities, you should carefully consider the specific
factors discussed under the caption &ldquo;Risk Factors&rdquo; in the applicable prospectus supplement, together with all of the other
information contained in the prospectus supplement or appearing or incorporated by reference in this prospectus. These risks could materially
affect our business, results of operations or financial condition and cause the value of our securities to decline. You could lose all
or part of your investment.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Changes to United States tariff and import/export regulations may have
a material adverse effect on our business, financial condition and results of operations.</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The United States has recently enacted and proposed
to enact significant new tariffs. Additionally, President Trump has directed various federal agencies to further evaluate key aspects
of U.S. trade policy and there has been ongoing discussion and commentary regarding potential significant changes to U.S. trade policies,
treaties and tariffs. There continues to exist significant uncertainty about the future relationship between the U.S. and other countries
with respect to such trade policies, treaties and tariffs. These developments, or the perception that any of them could occur, may have
a material adverse effect on global economic conditions and the stability of global financial markets, and may significantly reduce global
trade and, in particular, trade between the impacted nations and the U.S. Any of these factors could depress economic activity and restrict
our access to suppliers or customers and have a material adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>Government Action on tariffs and research grants and other funding may
impede our ability to conduct our research, conduct clinical trials and to raise capital.</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Early 2025 federal government actions to impose tariffs
and limit research grants and other funding, including funding universities and research enterprises, may cause disruption to our business.
These actions include the imposition of tariffs and ending or restructuring government research funding generally or in conjunction with
higher learning institutional funding. These government actions have been only recently implemented, therefore the full impact has yet
to be realized by the Company. Nonetheless, (i) tariffs are likely to increase the cost of doing business and to make it more difficult
to obtain items where imported equipment is required by our own activities and the activities of our collaborative and clinical research
partners, and (ii) ending or reducing research funding is likely to make it more difficult to find collaborative research partners and
to perform clinical studies to work with us on our research and clinical studies as government funding is an indirect support for our
research and product development activities. We also believe that as research funding to our collaborative research partners is reduced
or withdrawn, it will make raising capital for the Company more difficult, as investors will want to know if the Company will be able
to use the proceeds with fully funded entities.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><A NAME="a_006"></A>THE BUSINESS</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">We are a clinical stage immune-oncology company seeking
to advance treatments we believe will be first-in-class therapies that target known checkpoint resistance pathways to improve long-term
treatment response and quality of life in patients with invasive cancers.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">We attempt to source and develop early-to mid-stage
treatments that we believe will be first-in-class therapies for a variety of cancers, by funding, implementing viable, cost-effective
product development strategies, clinical counsel/trial design, shared services, financial and project management to enable efficient,
turnkey execution of commercially informed development plans. Our drug development focuses on product candidates or technologies based
on biology addressing known resistance pathways/mechanisms of current checkpoint inhibitors with established scientific rationales.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">In January 2024, due to funding deficiencies and uncertainty
in obtaining new funding, the company decided to discontinue its sponsored trial for its the invariant natural killer T-cell (iNKT) program;
in April 2024 it paused further patient accrual to its sponsored adenosine trial program (ADPORT-601 trial) for its potentially best-in-class
adenosine antagonists PORT-6 (A<SUB>2A</SUB> inhibitor) and PORT-7 (A<SUB>2B</SUB> inhibitor). In December 2024, Mr. Alexander Pickett
was appointed as Chief Executive Officer.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">In December 2024, the Company announced a letter of intent by which it would option its induced Natural Killer T-cell (iNKT) agonist
program to Immunova, LLC, a Connecticut-based biotechnology company. That letter of intent contemplated a definitive agreement that is
currently being negotiated.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">In January 2025, the company announced that it would
seek to finance its adenosine receptor antagonist program through private investment into the subsidiary containing those assets, to
be renamed Cyncado Therapeutics (&ldquo;Cyncado&rdquo;). Mr. Peter Molloy was appointed Chief Executive Officer of Cyncado to lead efforts
to secure external financing directly into Cyncado and to advance the clinical development of its portfolio of A<SUB>2A</SUB> and A<SUB>2B</SUB>
receptor antagonists. These therapeutics are distinguished by their potency, selectivity, and optimized binding characteristics, designed
to enable robust and sustained inhibition of immune suppression signals in the tumor microenvironment. Developed for dual administration
to maximize synergy and achieve a more comprehensive blockade of immune evasion pathways, these therapeutics aim to enhance the immune
system's ability to mount a robust anti-tumor response. This approach has the potential to transform immuno-oncology and deliver innovative,
well tolerated treatment options for patients. Cyncado is focused on advancing its clinical programs to achieve proof-of-concept data
for its therapeutics, further establishing their potential as transformative treatments in oncology.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">In March 2025, the company announced the resumption
of patient enrollment in the fourth and final cohort of the dose escalation stage for PORT-6, a highly selective A<SUB>2A</SUB> antagonist,
within its ADPORT-601 Phase 1b clinical trial. Portage had previously paused this trial due to funding concerns; this resumption of the
trial underscores the encouraging findings observed in earlier cohorts. After the completion of the PORT-6 arm of the ADPORT-601 study,
Portage will evaluate the continuation of the study into its PORT-7 (potent and selective A<SUB>2B</SUB> antagonist) and combination
arms, on a segment-by-segment basis.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Advancing to this final dose escalation reaffirms Portage&rsquo;s
confidence in the safety and therapeutic potential of PORT-6, bringing the company closer to identifying an optimal dose range for further
clinical development.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">In March 2025, the company separately announced the
presentation of new preclinical data for PORT-7 (TT-4), a selective Adenosine A<SUB>2B</SUB> receptor inhibitor, generated by Dr. Luciano
Mutti, Gruppo Italiano Mesotelioma e Oncologia Ambientale, at the 2025 European Lung Cancer Congress (ELCC), held in Paris, France March
26-29. The new data demonstrate both single agent activity for PORT-7, and a &gt;90% inhibition of tumor growth when PORT-7 was combined
with an anti-PD1 antibody in a murine model of mesothelioma. Mesothelioma is an aggressive cancer with limited treatment options in need
of novel approaches to overcome immune resistance. To our knowledge, this is the first report of antitumor activity against mesothelioma
using a selective A<SUB>2B</SUB> receptor inhibitor. Portage is making preparations to commence a first-in-human clinical trial with
PORT-7.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">At this time, the company has limited capital to fund
the business of Cyncado. The company and management of Cyncado are exploring different funding alternatives, however, there is no assurance
that there will be sufficient capital available, or available on satisfactory terms, to enable the business of Cyncado to progress.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The company also is exploring strategic alternatives,
which may include finding a partner for one or more of its assets, a sale of the company, sale of identified assets, a merger, various
corporate restructurings both in and out of court, a company wind down, further financing efforts or other strategic actions.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Corporate Information</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">We were originally incorporated in Ontario, Canada,
on April 9, 1973. The company was inactive until 1985. Then between 1986 and 2012, the company was engaged in variety of businesses. During
the period 1986 to 2012, the company went through several name changes ending with Bontan Corporation Inc. (Bontan).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">In December 2012, the company decided to change the
focus of its business activities, and in 2013, the company began its business focus within the biotechnology sector. On June 4, 2013,
the company acquired Portage Pharma Ltd., a biotech private limited company formed under the laws of the British Virgin Islands, by an
exchange of shares.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On July 5, 2013, the company changed its name to Portage
Biotech Inc. and moved its jurisdiction from Ontario, Canada, to the British Virgin Islands (BVI) under a certificate of continuance issued
by the Registrar of Corporate Affairs of the BVI.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The company now is a BVI business company limited by
shares with its registered office located at Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, BVI. Its United States agent
is Andrea Park, the Chief Financial Officer of the company, whose business address is 1111B S Governors Ave Ste 25907, Dover, Delaware
19904.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">We currently are a foreign private issuer under the
SEC rules. On February 25, 2021, our ordinary shares began trading on the Nasdaq Capital Market under the symbol &ldquo;PRTG&rdquo;. As
the principal market for our ordinary shares is Nasdaq, we voluntarily delisted our ordinary shares from the Canadian Securities Exchange
on April 23, 2021, where our ordinary shares had been trading.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">During 2018 we acquired a majority interest in SalvaRx Group plc. In January 2019, we completed the acquisition of SalvaRx Group plc,
which resulted in it becoming a wholly owned subsidiary. SalvaRx Group plc had full or partial ownership of four immune-oncology companies
including iOx Therapeutics (&ldquo;iOx&rdquo;) that were developing nine product candidates. Since then, development of each of these
candidates has been suspended.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On July 18, 2022, SalvaRx, entered into a Share Exchange
Agreement (the &ldquo;Share Exchange Agreement&rdquo;) with each of the minority shareholders of iOx (the &ldquo;Sellers&rdquo;) resulting
in the acquisition of the outstanding non-controlling ownership interest (approximately 22%) of iOx, which had been developing our iNKT
engager platform until we decided to pause further development earlier this year.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On July 1, 2022, we acquired Tarus Therapeutics,
Inc., a Delaware corporation advancing adenosine receptor antagonists for the treatment of solid tumors. On March 1, 2023, we,
through Tarus, entered into a clinical service agreement with a third-party service provider. The term of the agreement is through
February 20, 2026 or the completion of provision of services and the payment of contractual obligations or until the agreement is terminated for any reason and without cause on giving ninety (90) days' prior written notice of termination.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0"><I>Reverse Stock Split </I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">Our Board of Directors (the &ldquo;Board&rdquo;) approved
a reverse stock split of our ordinary shares at a ratio of 1-for-20. Beginning with the opening of trading on August 15, 2024, our ordinary
shares began trading on Nasdaq on a split-adjusted basis under the existing trading symbol &ldquo;PRTG&rdquo;.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">The reverse stock split was implemented to increase
the per share trading price of our ordinary shares for the purpose of ensuring a share price high enough to comply with the minimum $1.00
bid price requirement for continued listing on Nasdaq. The Company received notice from Nasdaq on August 30, 2024 informing the Company
that it had regained compliance with the minimum $1.00 bid price requirement for continued listing on Nasdaq.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">As a result of the reverse stock split, every twenty
(20) pre-split ordinary shares were converted into one (1) post-split ordinary share. Any fractional shares resulting from the reverse
stock split were rounded up to the nearest whole post-split ordinary share. The reverse stock split affected all shareholders uniformly
and did not alter any shareholder's percentage interest in our ordinary shares, except for adjustments that may result from the treatment
of fractional shares. All outstanding options and warrants entitling the holders to purchase our ordinary shares were adjusted as a result
of the reverse stock split, in accordance with the terms of each such security. In addition, the number of ordinary shares reserved for
future issuance pursuant to our equity incentive plan, as amended, was also appropriately adjusted. The number of authorized ordinary
shares was not proportionately reduced because we have an unlimited number of authorized ordinary shares available for issuance, as permitted
under the laws of the BVI.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">The share and loss per share information in the income
statements below have been retroactively adjusted to reflect the impact of the reverse stock split as if the stock split occurred at the
beginning of the periods presented. The shares of ordinary shares authorized remained at an unlimited number of ordinary shares without
par value.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">The following table reflects the loss and share data
used in the basic and diluted EPS calculations (U.S. Dollars in thousands, except per share amounts), as adjusted for the 1-for-20 reverse
stock split:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.25in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Years Ended March 31,</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; font-style: italic">Numerator (in 000&rsquo;$)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font-size: 10pt; font-weight: bold; text-align: left">Net loss attributable to owners of the Company</TD><TD STYLE="width: 1%; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">(75,339</TD><TD STYLE="white-space: nowrap; width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(104,611</TD><TD STYLE="white-space: nowrap; width: 1%; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left">Denominator (in 000&rsquo;)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">Weighted average number of shares &ndash; Basic and Diluted</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">968</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">806</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Basic and diluted loss per share</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">(77.83</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: right">(129.79</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; font-size: 10pt; font-weight: bold; text-align: left">)</TD></TR>
  </TABLE>


<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>


<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"><I>Other Matters</I></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The former CEO of the Company, Ian Walters, instituted a mediation pursuant to his prior services agreement with the Company
alleging that the Company did not pay him severance payments that he alleges he was contractually entitled to. The Company denies any
wrongdoing and maintains that his prior services agreement did not provide for severance in the event the agreement expired at the end
of the term. The parties unsuccessfully mediated the dispute on May 8, 2025 and the Company expects a litigation to be filed against the Company in
the coming weeks; in the event a motion is filed, the Company intends to defend itself vigorously against all charges.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"><I>Nasdaq Deficiency</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On December 10, 2024, the company received written
notice (the &ldquo;Notice&rdquo;) from The Nasdaq Stock Market, LLC (&ldquo;Nasdaq&rdquo;) indicating that it was not in compliance with
the minimum shareholders&rsquo; equity requirement for continued listing on The Nasdaq Capital Market (the &ldquo;Capital Market&rdquo;)
as set forth in Nasdaq Listing Rule 5550(b)(1) (the &ldquo;Shareholders&rsquo; Equity Requirement&rdquo;), because the shareholders&rsquo;
equity of $695,000 as of September 30, 2024, as reported in the company&rsquo;s Report on Form 6-K was below the required minimum of $2.5
million, and because as of the date of the Notice, the company did not meet either of the alternative continued listing standards for
the Capital Market, relating to market value of listed securities of at least $35 million or net income from continuing operations of
at least $500,000 in the most recently completed fiscal year or in two of the last three most recently completed fiscal years.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">As indicated in the Notice, the Company had a period
of 45 calendar days from the date of the Notice, or until January 24, 2025, to submit to Nasdaq a plan to regain compliance with the Shareholders&rsquo;
Equity Requirement or achieve compliance with an alternative continued listing standard for the Capital Market (the &ldquo;Compliance
Plan&rdquo;).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">On January 29, 2025, the company completed the sale
of 524,390 ordinary shares for aggregate proceeds of US$2,150,000, at a per share price of US$4.10 with two directors of the Company,
Messrs. Gregory Bailey and James Mellon. The shares were sold in a private placement transaction pursuant to Regulation S, and were
issued as restricted stock. The Company obtained a further extension period until June 9, 2025 to satisfy the Shareholders&rsquo;
Equity Requirement. If the company does not make progress consistent with its plan to raise additional capital and satisfy the listing
standards by that date, Nasdaq will initiate delisting proceedings as appropriate. At that time, the Company may appeal Nasdaq&rsquo;s
determination to a Hearings Panel.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Implications of Being a Foreign Private Issuer</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">We are a foreign private issuer within the meaning
of the rules under the Securities Exchange Act of 1934, as amended. As such, we are exempt from certain provisions applicable to U.S.
domestic public companies. For example:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27.35pt"></TD><TD STYLE="width: 9.35pt">&#9679;</TD><TD STYLE="text-align: justify">we are not required to provide as many Exchange Act reports, or as frequently, as a domestic public company;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27.35pt"></TD><TD STYLE="width: 9.35pt">&#9679;</TD><TD STYLE="text-align: justify">for interim reporting, we are permitted to comply solely with our home country requirements, which are
less rigorous than the rules that apply to domestic public companies;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27.35pt"></TD><TD STYLE="width: 9.35pt">&#9679;</TD><TD STYLE="text-align: justify">we are not required to provide the same level of disclosure on certain issues, such as executive compensation;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27.35pt"></TD><TD STYLE="width: 9.35pt">&#9679;</TD><TD STYLE="text-align: justify">we are exempt from provisions of Regulation FD aimed at preventing issuers from making selective disclosures
of material information;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27.35pt"></TD><TD STYLE="width: 9.35pt">&#9679;</TD><TD STYLE="text-align: justify">we are not required to comply with the sections of the Exchange Act regulating the solicitation of proxies,
consents or authorizations in respect of a security registered under the Exchange Act; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27.35pt"></TD><TD STYLE="width: 9.35pt">&#9679;</TD><TD STYLE="text-align: justify">we and our officers, directors and significant shareholders owning 10% or more of our equity are not required
to comply with Section 16 of the Exchange Act requiring insiders to file public reports of their share ownership and trading activities
and establishing insider liability for profits realized from any &ldquo;short-swing&rdquo; trading transaction.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>


<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B><A NAME="a_007"></A>USE OF PROCEEDS</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Unless otherwise indicated in the prospectus supplement,
the net proceeds from the sale of securities offered hereby will be used for general corporate purposes and working capital requirements,
which may include, among other things, the repayment or repurchase of debt obligations, redemption of outstanding equity securities and
other capital expenditures. We may also use a portion of the net proceeds for licensing or acquiring intellectual property or technologies
to incorporate into our products and product candidates or our research and development programs, capital expenditures, to fund possible
investments in and acquisitions of complementary businesses or partnerships. We may also use the proceeds to fund strategic alternatives
that we may pursue, such as a sale of the company, sale of assets, a merger, various corporate restructurings both in and out of court,
a company wind down, further financing efforts or other strategic actions. We have not determined the amounts we plan to spend on the
areas listed above or the timing of these expenditures, and we have no current plans with respect to acquisitions, dispositions or restructurings
as of the date of this prospectus. As a result, unless otherwise indicated in the prospectus supplement, our management will have broad
discretion to allocate the net proceeds of the offerings. Pending their ultimate use, we intend to invest the net proceeds in a variety
of securities, including commercial paper, government and non-government debt securities and/or money market funds that invest in such
securities.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B><A NAME="a_008"></A>DESCRIPTION OF THE ORDINARY SHARES WE MAY OFFER</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>The following description of our ordinary shares
is only a summary. This description and the description contained in any prospectus supplement is subject to, and qualified in its entirety
by reference to, our memorandum and articles of association, the memorandum and articles, each as amended from time to time, which has
previously been filed with the SEC and in the Territory of the British Virgin Islands, pursuant to the BVI Business Companies Act (Revised
Edition 2020), as amended (referred to as the &ldquo;BVI Act&rdquo;).</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Share Capital</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Pursuant to our Memorandum and Articles of Association,
we are authorized to issue an unlimited number of ordinary shares of no-par value.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Meetings of shareholders</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">If our shareholders want us to hold a meeting of shareholders
of the company, they may requisition the directors to hold one upon the written request of shareholders entitled to exercise at least
10% of the voting rights in respect of the matter for which the meeting is requested. Under British Virgin Islands law, this 10% threshold
may only be increased to a maximum of 30% and any such increase would require an amendment to the Memorandum and Articles of Association.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Subject to our Memorandum and Articles of Association,
a meeting of shareholders of the company will be called by not less than ten days' written notice and no more than 60 days&rsquo; notice.
Notice of every meeting of shareholders may be delivered electronically and will be given to all of our shareholders. However, the inadvertent
failure of the convener or conveners of a meeting of shareholders to give notice of the meeting to a shareholder, or the fact that a shareholder
has not received the notice, does not invalidate the meeting.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">A meeting of shareholders is duly constituted if, at
the commencement of the meeting, there are present in person or by proxy two or more shareholders entitled to vote at the meeting.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The directors may decide to hold a meeting of shareholders
as a physical meeting or a virtual meeting or a hybrid meeting as set out in more detail in the Memorandum and Articles of Association</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Voting rights</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Holders of our ordinary shares have identical rights,
including dividend and liquidation rights, except as otherwise expressly provided in our Amended Memorandum and Articles of Association
or required by applicable law. On any matter that is submitted to a vote of our shareholders, holders of our ordinary shares are entitled
to one vote per ordinary share.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Under the BVI Act, the ordinary shares are deemed to
be issued when the name of the shareholder is entered in our register of members. Our register of members is maintained by our transfer
agent, TSX Trust Company, which enters the names of our shareholders in our register of members. If (a) information that is required to
be entered in the register of shareholders is omitted from the register or is inaccurately entered in the register, or (b) there is unreasonable
delay in entering information in the register, a shareholder of the company, or any person who is aggrieved by the omission, inaccuracy
or delay, may apply to the British Virgin Islands courts for an order that the register be rectified, and the court may either refuse
the application or order the rectification of the register, and may direct us to pay all costs of the application and any damages the
applicant may have sustained.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>


<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Subject to any rights or restrictions attached to any
shares, at any general meeting on a show of hands every shareholder of record who is present in person (or, in the case of a shareholder
being a corporation, by its duly authorized representative) or by proxy shall have one vote and on a poll every shareholder present in
person (or, in the case of a shareholder being a corporation, by its duly appointed representative) or by proxy shall have one vote for
each share which such shareholder is the holder. Voting at any meeting of the shareholders is by show of hands unless a poll is demanded.
A poll may be demanded by shareholders present in person or by proxy if the shareholder disputes the outcome of the vote on a proposed
resolution and the chairman shall cause a poll to be taken. In the case of a tie vote at a meeting of shareholders, the chairman shall
be entitled to a second or casting vote.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">No shareholder shall be entitled to vote or be reckoned
in a quorum, in respect of any share, unless such shareholder is registered as our shareholder at the applicable record date for that
meeting. Shareholders of record may also pass written resolutions without a meeting by a majority vote.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Protection of minority shareholders</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Under the laws of the British Virgin Islands, there
is little statutory law for the protection of minority shareholders other than the provisions of the BVI Act dealing with shareholder
remedies. The principal protection under statutory law is that shareholders may bring an action to enforce the BVI Act or the constituent
documents of the corporation, our Memorandum and Articles of Association. Shareholders are entitled to have our affairs conducted in accordance
with the BVI Act and the Memorandum and Articles of Association. Pursuant to Section 184B of the BVI Act, if a company or director of
a company engages in, or proposes to engage in or has engaged in, conduct that contravenes the provisions of the BVI Act or the memorandum
or articles of association of the company, the British Virgin Islands Court may, on application of a shareholder or director of the company,
make an order directing the company or director to comply with, or restraining the company or director from engaging in conduct that contravenes
the BVI Act or the memorandum or articles. Furthermore, pursuant to section 184I(1) of the BVI Act a shareholder of a company who considers
that the affairs of the company have been, are being or likely to be, conducted in a manner that is, or any acts of the company have been,
or are likely to be oppressive, unfairly discriminatory, or unfairly prejudicial to him in that capacity, may apply to the British Virgin
Islands Court for an order which, inter alia, can require the company or any other person to pay compensation to the shareholders</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">There are common law rights for the protection of shareholders
that may be invoked, largely dependent on English company law, since the common law of the British Virgin Islands is limited. Under the
general rule pursuant to English company law known as the rule in Foss v. Harbottle, a court will generally refuse to interfere with the
management of a company at the insistence of a minority of its shareholders who express dissatisfaction with the conduct of the company's
affairs by the majority or the board of directors. However, every shareholder is entitled to have the affairs of the company conducted
properly according to British Virgin Islands law and the constituent documents of the company. As such, if those who control the company
have persistently disregarded the requirements of the BVI Act or the provisions of the company's Memorandum and Articles of Association,
then the courts may grant relief. Generally, the areas in which the courts will intervene are the following: (1) an act complained of
which is outside the scope of the authorized business or is illegal or not capable of ratification by the majority; (2) acts that constitute
fraud on the minority where the wrongdoers control the company; (3) acts that infringe or are about to infringe on the personal rights
of the shareholders, such as the right to vote; and (4) where the company has not complied with provisions requiring approval of a special
or extraordinary majority of shareholders, which are more limited than the rights afforded minority shareholders under the laws of many
states in the U.S.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Pre-emption rights</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">British Virgin Islands law does not make a distinction
between public and private companies and some of the protections and safeguards (such as statutory pre-emption rights) that investors
may expect to find in relation to a public company are not provided for under British Virgin Islands law, save to the extent they are
expressly provided for in the Memorandum and Articles of Association. There are no pre-emption rights applicable to the issuance of new
shares by us under either British Virgin Islands law generally or our Memorandum and Articles of Association more specifically.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>Modification of rights</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">As permitted by British Virgin Islands law, and our
Memorandum and Articles of Association, we may vary the rights attached to our ordinary shares.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Transfer of shares</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Subject to any applicable restrictions set forth in
our Memorandum and Articles of Association, any of our shareholders may transfer all or any of his or her shares by a written instrument
of transfer in the usual or common form or in any other form which our directors may approve. Shares may be held electronically and transferred
electronically.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The registration of transfers may be suspended at such
times and for such periods as the directors may from time to time determine. If the directors were to refuse (or suspend) a transfer,
then the directors should provide the transferor and transferee with a notice providing their reasons for the suspension. The directors
may refuse or delay the registration of a transfer of shares if the transferor has failed to pay amount due in respect of those shares.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Changes in authorized ordinary shares</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">By resolution of our directors we may (i) consolidate
and divide all or any of our unissued authorized shares into shares of larger amount than our existing shares; (ii) sub-divide our existing
ordinary shares, or any of them into shares of smaller amount than is fixed by our memorandum of association, subject nevertheless to
the provisions of the BVI Act; or (iii) create new classes of shares with preferences to be determined by the board of directors at the
time of authorization.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Dividends</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Subject to the BVI Act and our Memorandum and Articles
of Association, our directors may, by resolution, authorize a distribution to shareholders at such time and of such an amount as they
think fit, if they are satisfied, on reasonable grounds, that, immediately after the distribution, we will satisfy the 'solvency test'.
A company will satisfy the solvency test if (i) the value of the company's assets exceeds its liabilities; and (ii) the company is able
to pay its debts as they fall due. Where a distribution is made to a shareholder at a time when the company did not, immediately after
the distribution, satisfy the solvency test, it may be recovered by the company from the shareholder unless (i) the shareholder received
the distribution in good faith and without knowledge of the company's failure to satisfy the solvency test; (ii) the shareholder has altered
his position in reliance on the validity of the distribution; and (iii) it would be unfair to require repayment in full or at all.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Share repurchases</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">As permitted by the BVI Act and our Memorandum and
Articles of Association, shares may be repurchased, redeemed or otherwise acquired by us provided that, immediately following the repurchase
or redemption, we are satisfied we will pass the aforementioned solvency test.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">We will require member consent before any share can
be purchased, redeemed or otherwise acquired by us, save where such redemption is pursuant to certain statutory provisions, such as pursuant
to section 179 of the BVI Act (redemption of minority shares) which allows for the holders of 90% or more of the votes to instruct the
company to redeem the shares of the company held by the remaining shareholders.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>Liquidation rights</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">As permitted by British Virgin Islands law and our
Memorandum and Articles of Association, a voluntary liquidator may be appointed under Part XII of the BVI Act if we satisfy the solvency
test (as aforementioned save that it is satisfied if assets equal or exceed liabilities).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Board of directors</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">We are managed by a board of directors, which consisted
of six directors at March 31, 2025. Our Memorandum and Articles of Association provide that the board of directors may be established
by the board of directors up to a maximum of 15 members.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Our shareholders may, pursuant to our Memorandum and
Articles of Association, by resolution of shareholders passed at a meeting of shareholders called for the purpose of removing the director
or for purposes including the removal of the director or by a written resolution of shareholders at any time remove any director before
the expiration of his or her period of office with or without cause, and may, pursuant to our Memorandum and Articles of Association,
elect another person in his or her stead. Subject to our Memorandum and Articles of Association, the directors will have power at any
time and from time to time to appoint any person to be a director, either as an addition to the existing directors or to fill a vacancy
as long as the total number of directors (exclusive of alternate directors) does not at any time exceed the maximum number fixed by or
in accordance with our Memorandum and Articles of Association (if any) and one third times the number of directors to have been elected
at the last annual meeting of shareholders. Our Memorandum and Articles of Association do not permit directors to appoint alternate directors.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">There are no share ownership qualifications for directors,
unless otherwise decided by a resolution of shareholders. Meetings of our board of directors may be convened at any time deemed necessary
by any of our directors.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Unless the quorum has been otherwise fixed by the board,
a meeting of our board of directors will be competent to make lawful and binding decisions if a majority of the directors are present
or represented. Unless there are only two directors, in which case, the quorum shall be two. At any meeting of our directors, each director
present is entitled to one vote.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Questions arising at a meeting of our board of directors
are required to be decided by simple majority votes of the directors' present or represented at the meeting. In the case of a tie vote,
the chairman of the meeting shall not have a second or deciding vote. Our board of directors may also pass written resolutions without
a meeting by a majority vote.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The remuneration to be paid to the directors shall
be such remuneration as the directors or shareholders shall determine through a resolution.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Issuance of additional ordinary shares</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Our Memorandum and Articles of Association authorize
our board of directors to issue additional ordinary shares from time to time as our board of directors shall determine, to the extent
of available authorized but unissued shares.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Our Memorandum and Articles of Association authorize
our board of directors from time to time to issue ordinary shares to the extent permitted by the BVI Act.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Changes in authorized shares</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">We are authorized to issue unlimited number of ordinary
shares without par value, which will be subject to the same provisions with reference to the payment of calls, liens, transfers, transmissions,
forfeitures and otherwise as the shares in issue. By resolution of directors we may:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify">&#9679;</TD>
    <TD STYLE="width: 97%; text-align: justify">consolidate and divide all or any of our unissued authorized shares into shares of a larger amount than our existing shares;</TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0 0pt 0.5in; font-size: 10pt; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify">&#9679;</TD>
    <TD STYLE="width: 97%; text-align: justify">sub-divide our existing ordinary shares, or any of them into shares of smaller amount than is fixed by our memorandum of association, subject nevertheless to the provisions of the BVI Act; and by resolution of shareholders we may</TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify">&#9679;</TD>
    <TD STYLE="width: 97%; text-align: justify">create new classes of shares with preferences to be determined by the board of directors at the time of authorization.</TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Inspection of books and records</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Under British Virgin Islands law holders of our ordinary
shares will be entitled, on giving written notice to us, to inspect and make copies or take extracts of our: (a) Memorandum and Articles
of Association; (b) register of shareholders; (c) register of directors; and (d) minutes of meetings and resolutions of shareholders and
those classes of shareholders of which he is a shareholder.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Subject to our Memorandum and Articles of Association,
our board of directors may, if they are satisfied that it would be contrary to our interest to allow a shareholder to inspect any document,
or part of a document as referenced above, refuse to permit the shareholder to inspect the document or limit the inspection of the document,
including limiting the making of copies or the taking of extracts from the records. Where our directors exercise their powers in these
circumstances, they shall notify the shareholder as soon as reasonably practicable.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Conflicts of interest</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Pursuant to the BVI Act and the company's Memorandum
and Articles of Association, a director of a company who has an interest in a transaction and who has declared such interest to the other
directors, may:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify">&#9679;</TD>
    <TD STYLE="width: 97%; text-align: justify">vote on a matter relating to the transaction;</TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify">&#9679;</TD>
    <TD STYLE="width: 97%; text-align: justify">attend a meeting of directors at which a matter relating to the transaction arises and be included among the directors present at the meeting for the purposes of a quorum; and</TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify">&#9679;</TD>
    <TD STYLE="width: 97%; text-align: justify">sign a document on behalf of the company or do any other thing in his capacity as a director, that relates to the transaction.</TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Anti-money laundering laws</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">In order to comply with legislation or regulations
aimed at the prevention of money laundering we are required to adopt and maintain anti-money laundering procedures and may require subscribers
to provide evidence to verify their identity. Where permitted, and subject to certain conditions, we may also delegate the maintenance
of our anti-money laundering procedures (including the acquisition of due diligence information) to a suitable person.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">We reserve the right to request such information as
is necessary to verify the identity of a subscribe for our ordinary shares. In the event of delay or failure on the part of the subscriber
in producing any information required for verification purposes, we may refuse to accept the application, in which case any funds received
will be returned without interest to the account from which they were originally debited.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">If any person resident in the British Virgin Islands
knows or suspects that another person is engaged in money laundering or terrorist financing and the information for that knowledge or
suspicion came to their attention in the course of their business, the person will be required to report his belief or suspicion to the
Financial Investigation Agency of the British Virgin Islands, pursuant to the Proceeds of Criminal Conduct Act 1997 (Revised Edition 2020)
as amended. Such a report shall not be treated as a breach of confidence or of any restriction upon the disclosure of information imposed
by any enactment or otherwise.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>Duties of directors</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">British Virgin Islands law provides that every director
of the company in exercising his powers or performing his duties shall act honestly and in good faith and in what the director believes
to be in the best interests of the company. Additionally, the director shall exercise the care, diligence, and skill that a reasonable
director would exercise in the same circumstances taking into account the nature of the company, the nature of the decision and the position
of the director and his responsibilities. In addition, British Virgin Islands law provides that a director shall exercise his powers as
a director for a proper purpose and shall not act, or agree to the company acting, in a manner that contravenes British Virgin Islands
law or the memorandum and articles of association of the company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Anti-takeover provisions</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The BVI Act does not prevent companies from adopting
a wide range of defensive measures, such as staggered boards, blank check preferred shares, removal of directors only for cause and provisions
that restrict the rights of shareholders to call meetings and submit shareholder proposals<I>.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Voting rights and quorum requirements</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Under British Virgin Islands law, the voting rights
of shareholders are regulated by the company's Memorandum and Articles of Association and, in certain circumstances, the BVI Act. The
articles of association will govern matters such as quorum for the transaction of business, rights of shares, and majority votes required
to approve any action or resolution at a meeting of the shareholders or board of directors. Unless the articles of association otherwise
provide, the requisite majority is usually a simple majority of votes cast. Under the Memorandum and Articles of Association, a resolution
of shareholders requires a majority vote of those persons voting at a meeting or in the case of a written resolution of shareholders,
the vote of a majority of the shareholders.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Mergers and similar arrangements</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Under the BVI Act, two or more companies may merge
or consolidate in accordance with the statutory provisions. A merger means the merging of two or more constituent companies into one of
the constituent companies, and a consolidation means the uniting of two or more constituent companies into a new company. In order to
merge or consolidate, the directors of each constituent company must approve a written plan of merger or consolidation which must be authorized
by a resolution approved, at a duly convened and constituted meeting of the shareholders of the Company, by the affirmative vote of a
majority of those persons voting at a meeting or in the case of a written resolution of shareholders, the vote of a majority of the shareholders.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Shareholders not otherwise entitled to vote on the
merger or consolidation may still acquire the right to vote if the plan or merger or consolidation contains any provision which, if proposed
as an amendment to the memorandum of amended association and articles of association, would entitle them to vote as a class or series
on the proposed amendment. In any event, all shareholders must be given a copy of the plan of merger or consolidation irrespective of
whether they are entitled to vote at the meeting or consent to the written resolution to approve the plan of merger or consolidation.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Shareholder suits</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">We are not aware of any reported class action or derivative
action having been brought against the company in a British Virgin Islands court.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Under the BVI Act, if a company or a director of a
company engages in, or proposes to engage in, conduct that contravenes the BVI Act or the memorandum of association or articles of the
company, the BVI Court may, on the application of a shareholder or a director of the company, make an order directing the company or director
to comply with, or restraining the company or director from engaging in that conduct.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">In addition, under the BVI Act, the BVI Court may,
on the application of a shareholder of a company, grant leave to that shareholder to bring proceedings in the name and on behalf of that
company or to intervene in proceedings to which the company is a party for the purpose of continuing, defending or discontinuing the proceedings
on behalf of the company. In determining whether to grant leave for such derivative actions, the Court must take into account certain
matters, including whether the shareholder is acting in good faith, whether the derivative action is in the interests of the company taking
account of the views of the company's directors on commercial matters and whether an alternative remedy to the derivative claim is available.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">A shareholder of a company may bring an action against
the company for breach of a duty owed by the company to him as a shareholder. The BVI Act also includes provisions for actions based on
oppression, and for representative actions where the interests of the claimant are substantially the same as those of other shareholders.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Corporate governance</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">British Virgin Islands laws do not restrict transactions
between a company and its directors, requiring only that directors exercise a duty to act honestly, in good faith and in what the directors
believe to be in the best interests to the companies for which they serve.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Indemnification</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">British Virgin Islands law does not limit the extent
to which a company's memorandum and articles of association may provide for indemnification of officers and directors, except to the extent
any such provision may be held by the British Virgin Islands courts to be contrary to public policy, such as to provide indemnification
against civil fraud or the consequences of committing a crime. Our Memorandum and Articles of Association provide for the indemnification
of our directors (past and present) against all losses or liabilities incurred or sustained by a director as a director of our company
in defending any proceedings, whether civil or criminal and this indemnity only applies if he or she acted honestly and in good faith
with a view to our best interests and, with respect to any criminal action, he or she must have had no reasonable cause to believe his
or her conduct was unlawful.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Insofar as indemnification for liabilities arising
under the Securities Act may be permitted for directors, officers or persons controlling us under the foregoing provisions, we have been
advised that, in the opinion of the U.S. Securities and Exchange Commission, such indemnification is against public policy as expressed
in the Securities Act and therefore is unenforceable.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Staggered board of directors</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The BVI Act does not contain statutory provisions that
require staggered board arrangements for a British Virgin Islands company and our Memorandum and Articles of Association do not provide
for a staggered board.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Differences in Corporate Law</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The BVI Act differs from laws generally applicable
to United States corporations and their shareholders. Set forth below is a brief summary of significant differences between the provisions
of the BVI Act applicable to us and the laws applicable to companies incorporated in the United States. The discussion of the variations
does not cover any requirements of a stock exchange, trading medium or any applicable securities laws.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Protection for Minority Shareholders.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Under the laws of most U.S. jurisdictions, majority
and controlling shareholders of a company generally have certain &quot;fiduciary&quot; responsibilities to the minority shareholders.
Corporate actions taken by majority and controlling shareholders which are unreasonable and materially detrimental to the interest of
minority shareholders may be declared null and void. See above for a discussion of the BVI Act provision relating to the protection of
minority shareholders. The availability and interpretation of minority shareholder rights under British Virgin Islands law may differ
from the position in the United States, even in relation to laws which may appear to be analogous. Similarly, the exercise and enforcement
of such rights may involve seeking remedies under foreign law before a court or tribunal outside the United States, where the procedure
and outcome may differ from what might apply or eventuate in a court in the United States.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The BVI Act also provides that shareholders of the
company owning 90% of the votes entitled to be voted may cause the company to redeem the shares held by the remaining shareholders.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I></I></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"><I>Powers of Directors.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The powers of directors under most US jurisdictions
is similar to that of the BVI Act. Generally, the sale of the significant asset or combination of assets of a company requires the approval
of the shareholders of a United States company. The directors of a British Virgin Islands company, subject in certain cases to the approval
of the court (which will generally require shareholder approval), may implement the sale, transfer, exchange or disposition of any asset,
property, part of the business, or securities of the company, if the board determines such transaction to be in the best interests of
the company, its creditors, or its shareholders, with the exception that shareholder approval may be required for any sale, transfer,
lease exchange or other disposition of more than 50% in value of the assets of the company other than in the usual or regular course of
business of the company. The BVI Act, however, provides that the memorandum and articles of a company may exclude application of the above
shareholder approval requirement for the disposition of 50% or more of the assets as set forth in Section 175 of the BVI Act. Our Memorandum
and Articles of Association incorporates the exclusion; therefore our directors may act to sell or otherwise dispose of any or all the
assets of the company without restriction and without complying with section 175 of the BVI Act.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Although our Memorandum and Articles of Association
exclude the possibility of alternate directors, under the BVI Act, subject to the Memorandum and Articles of Association any director
of the company may in writing appoint another person, who need not be a director, to be his alternate, provided such person has consented
in writing to be an alternate director. An alternate director has the same rights as the appointing director in relation to any director's
meeting and any written resolution circulated for written consent. Every such alternate director shall therefore be entitled to attend
meetings in the absence of the director who appointed him and to vote in the place of the director and sign written consents. Where the
alternate is a director he shall be entitled to have a separate vote on behalf of the director he is representing in addition to his own
vote. A director may at any time in writing revoke the appointment of an alternate appointed by him. An alternate director may not be
an officer of the company. The remuneration of an alternate director shall be payable out of the remuneration of the director appointing
him and the proportion thereof shall be agreed between them. United States corporate laws does not provide for alternate directors.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Conflict of Interests.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Similar to the laws of most United States jurisdictions,
under the BVI Act when a director becomes aware of the fact that he has an interest in a transaction which the company is to enter into,
he must disclose it to the board. With sufficient disclosure of the interest in relation to that transaction, the director who is interested
in a transaction entered into or to be entered into by us may (i) vote on a matter relating to the transaction&#894; (ii) attend a meeting
of directors at which a matter relating to the transaction arises and be included in the quorum&#894; and (iii) sign a document on behalf
of the company, or do any other thing in his capacity as a director, that relates to the transaction. If there is required disclosure
by a director, which is not made, then the transaction is voidable by the company, unless the transaction is one that is an ordinary course
transaction of the company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Written Consent and Cumulative Voting.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Similar to the laws of most U.S. jurisdictions, under
the British Virgin Islands law, shareholders are permitted to approve matters by way of written resolution in place of a formal meeting.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Under corporate law in United States jurisdictions,
the certificate of incorporation may provide for cumulative voting in an election of directors. The BVI Act does not make a specific reference
to cumulative voting, and our current Memorandum and Articles of Association have no provisions authorizing cumulative voting.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Independent Directors.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Similar to corporate law in Untied States jurisdictions,
there is no requirement for a majority, or for that matter any, of the directors of the company to be independent under British Virgin
Islands law. The regulations of a securities exchange on which securities of a company are listed often require independent directors.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I></I></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in"><I>Forfeiture of Shares.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Although we intend to only sell our shares upon receipt
of the full purchase price, if shares are not fully paid, then under our Memorandum and Articles of Association and the BVI Act any shares
that are not fully paid are subject to forfeiture. The company has the right to demand full payment at any time, upon notice served on
the shareholder stating the time and amount due, and advising the shareholder that if the payment is not made then the shares will be
forfeited and cancelled. Any funds paid in respect of shares which are subsequently forfeited is non-refundable. Under United States corporate
law, shares are usually required to be paid in full at the time of issuance.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Redemption and Treasury Shares.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Similar to the law of United States jurisdictions,
a BVI company may purchase, redeem or otherwise acquire and hold its own shares in treasury or cancel them in such manner and upon such
other terms as the directors may agree with the relevant shareholder(s). Also, similar to the law of Untied States jurisdictions, we may
redeem our shares only with the consent of the shareholders whose shares are to be redeemed. The consent from the shareholders is not
needed under the circumstances of the compulsory redemption, at the request of the shareholders holding 90% of the votes of the outstanding
shares entitled to vote, of the remaining issued shares. Under the law of United States jurisdictions, shareholders with less than 10%
(and in some cases 5%) of the outstanding shares may be forced to sell their shares to the company, upon a decision only of the board
of directors.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Takeover Provisions.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The BVI Act does not provide anti-takeover measures,
similar to some jurisdictions in the United States. Generally, our Memorandum and Articles of Association do not introduce anti-takeover
measures. For example, we have shareholder action permitted by written consent, directors may be removed with or without cause, and we
do not have staggered board appointments. While we do not have any other class of equity authorized, which could have anti-takeover effect,
we do have unlimited ordinary shares and could use them for an anti-takeover plan or action, such as a poison pill plan, which would have
to be in place before a takeover offer is in contemplation, as, if not, the directors might be seen as exercising their powers for an
improper purpose in trying to introduce such a measure.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Notwithstanding the foregoing, the company could consider
and adopt anti-takeover measures. Some of these require an amendment to our Memorandum and Articles of Association, which would have to
be approved by way of director and/or shareholder resolutions.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Shareholder's Access to Corporate Records.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Similar to the corporate laws in the United States,
a shareholder is entitled, on giving written notice to the company, to inspect the company's (i) memorandum and articles of association&#894;
(ii) register of members&#894; (iii) register of directors&#894; and (iv) minutes of meetings and resolutions of members and of those
classes of members of which he is a member. A shareholder is also entitled to copies of the records. Notwithstanding the foregoing, the
directors may limit access to company records it is contrary to the company interests. However, where a shareholder is denied access to
the company records, the shareholder may apply to the courts for an order to permit access and copying. In some jurisdictions in the United
States, there has been limitations imposed on the scope of access to corporate records, and generally access is only for a legitimate
purpose related to the position of being a shareholder.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Indemnification.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Similar to the corporate law in the United States,
British Virgin Islands law does not limit the extent to which a company's memorandum and articles of association may provide for indemnification
of officers and directors, except to the extent any such provision may be held by the British Virgin Islands courts to be contrary to
public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Our Memorandum and Articles of Association provide
for the indemnification of our directors (past and present) against all losses or liabilities incurred or sustained by a director as a
director of our company in defending any proceedings, whether civil or criminal and this indemnity only applies if he or she acted honestly
and in good faith with a view to our best interests and, with respect to any criminal action, he or she must have had no reasonable cause
to believe his or her conduct was unlawful.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">We may purchase and maintain insurance in relation
to any person who is or was a director, or who at the request of the company is or was serving as a director of, or in any other capacity
is or was acting for another body corporate or a partnership, joint venture, trust or other enterprise, against any liability asserted
against the person and incurred by the person in that capacity, whether or not the Company has or would have had the power to indemnify
the person against the liability.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Mergers and Similar Arrangements.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The BVI Act provides for the merger and other combination
arrangements for companies. In order to merge or consolidate, the directors of each constituent company must approve a written plan of
merger or consolidation which must be authorized by a resolution of shareholders.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">While a director may vote on a merger or consolidation
even if he has a financial interest in the plan of merger of consolidation, in order for the resolution to be valid and the transaction
not voidable, the interest must have been disclosed to the board forthwith upon him becoming aware of such interest. The transaction will
not be voidable if the shareholders approve it.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Shareholders not otherwise entitled to vote on a merger
or consolidation may still acquire the right to vote if the plan of merger or consolidation contains any provision which, if proposed
as an amendment to the memorandum or articles of association, would entitle them to vote as a class or series on the proposed amendment.
In any event, all shareholders must be given a copy of the plan of merger or consolidation irrespective of whether they are entitled to
vote at the meeting or consent to the written resolution to approve the plan of merger or consolidation.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The shareholders of the constituent companies are not
required to receive shares of the surviving or consolidated company but may receive cash, debt obligations or other securities of the
surviving or consolidated company, or other assets, or a combination thereof. Further, some or all of the shares of a class or series
may be converted into a kind of asset while the other shares of the same class or series may receive a different kind of asset. As such,
not all the shares of a class or series must receive the same kind of consideration.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">After the plan of merger or consolidation has been
approved by the directors and authorized by a resolution of the shareholders, articles of merger or consolidation are executed by each
company and filed with the Registrar of Corporate Affairs in the British Virgin Islands.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">A shareholder may dissent from a mandatory redemption
of his shares, an arrangement (if permitted by the court), a merger (unless the shareholder was a shareholder of the surviving company
prior to the merger and continues to hold the same or similar shares after the merger) and a consolidation. A shareholder properly exercising
his dissenter rights is entitled to payment of the fair value of their shares.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">A shareholder dissenting from a merger or consolidation
must object in writing to the merger or consolidation before the vote by the shareholders on the merger or consolidation, unless notice
of the meeting was not given to the shareholder. If the merger or consolidation is approved by the shareholders, the company must within
20 days give notice of this fact to each shareholder who gave written objection, and to each shareholder who did not receive notice of
the meeting. Such shareholders then have 20 days to give to the company their written election in the form specified by the BVI Act to
dissent from the merger or consolidation, provided that in the case of a merger, the 20 days starts when the plan of merger is delivered
to the shareholder.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Upon giving notice of his election to dissent, a shareholder
ceases to have any rights of a shareholder except the right to be paid the fair value of his shares. As such, the merger or consolidation
may proceed in the ordinary course notwithstanding the dissent.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Within seven days of the later of the delivery of the
notice of election to dissent and the effective date of the merger or consolidation, the company must make a written offer to each dissenting
shareholder to purchase his shares at a specified price that the company determines to represent fair value. The company and the shareholder
then have 30 days to agree upon the price. If the company and the shareholder fail to agree on the price within the 30 days, then the
company and the shareholder shall each designate an appraiser and these two appraisers shall designate a third appraiser. These three
appraisers shall fix the fair value of the shares as of the close of business on the day before the shareholders approved the transaction
without taking into account any change in value as a result of the transaction.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>Shareholders' Suits.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Similar to the corporate laws in the United States,
the BVI Act permits derivative actions against its directors. However, the circumstances under which such actions may be brought, and
the procedures and defenses available under British Virgin Islands law may result in the rights of shareholders of a British Virgin Islands
company being more limited than those of shareholders of a company incorporated and/or existing in the United States.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The British Virgin Islands does not have provision
for &quot;class actions.&quot; It does however provide for &quot;representative action&quot;, whereby a representative may be appointed
to represent parties with the same interest. In such cases those parties will typically be bound by any decision in the proceedings. The
BVI Act specifically provides for the process by which a claim may be brought &quot;derivatively&quot; on behalf of a company by one of
its shareholders. Importantly, proceedings may not be brought by a shareholder without leave of the court. The courts of the British Virgin
Islands may, on the application of a shareholder of a company, grant leave to that shareholder to bring proceedings in the name and on
behalf of that company, or intervene in proceedings to which the company is a party for the purpose of continuing, defending or discontinuing
the proceedings on behalf of the company. In determining whether to grant leave, the High Court of the British Virgin Islands must take
into account (i) whether the shareholder is acting in good faith. (ii) whether the derivative action is in the interests of the company
taking account of the views of the company's directors on commercial matters. (iii) whether the proceedings are likely to succeed. (iv)
the costs of the proceedings in relation to the relief likely to be obtained. and (v) whether an alternative remedy to the derivative
claim is available.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Leave to bring or intervene in proceedings may be granted
only if the High Court of the British Virgin Islands is satisfied that (i) the company does not intend to bring, diligently continue or
defend, or discontinue the proceedings, as the case may be or (ii) it is in the interests of the company that the conduct of the proceedings
should not be left to the directors or to the determination of the shareholders as a whole.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Any member of a company may apply to the British Virgin
Islands Court under the Insolvency Act (Revised Edition 2020) as amended for the appointment of a liquidator to liquidate the company
and the court may appoint a liquidator for the company if it is of the opinion that it is just and equitable to do so.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Anti-Takeover Effect of Authorized but Unissued Ordinary Shares</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The BVI Act does not require shareholder approval for
any issuance of our ordinary shares. The ordinary shares that may be issued under our Memorandum and Articles of Association may be used
for a variety of corporate purposes, including future public offerings, to raise additional capital or to facilitate acquisitions. One
of the effects of the existence of unissued and unreserved ordinary shares may be to enable our board of directors to sell shares to persons
friendly to current management, for such consideration, in form and amount, as is acceptable to the board of directors, which issuance
could render more difficult or discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise,
and thereby protect the continuity of our management and possibly deprive shareholders of opportunities to sell their ordinary shares
at prices higher than prevailing market prices.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The BVI Act does not make a specific reference to cumulative
voting, and our current Memorandum and Articles of Association have no provisions authorizing cumulative voting.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B><A NAME="a_009"></A>DESCRIPTION OF WARRANTS WE MAY OFFER</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"><I>The following description of warrants is only a
summary. This description is subject to, and qualified in its entirety by reference to, the provisions of the applicable warrant agreement.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">We may issue warrants for the purchase of ordinary
shares or units. Warrants may be issued independently or together with ordinary shares or units and may be attached to or separate from
any other offered securities. Any issuance of warrants will be governed by the terms of the applicable form of warrant and any related
warrant agreement, which we will file as an exhibit to our registration statement at or before the time we issue any warrants.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The particular terms of any issue of warrants will
be described in the prospectus supplement relating to the issue. Those terms may include:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">&#8226;</TD><TD>the
title of such warrants;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">&#8226;</TD><TD>the
aggregate number of such warrants;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">&#8226;</TD><TD>the
price or prices at which such warrants will be issued;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">&#8226;</TD><TD>the
currency or currencies (including composite currencies) in which the price of such warrants may be payable;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">&#8226;</TD><TD>the
terms of the securities purchasable upon exercise of such warrants and the procedures and conditions relating to the exercise of such
warrants;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">&#8226;</TD><TD>the
price at which the securities purchasable upon exercise of such warrants may be purchased;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">&#8226;</TD><TD>the
date on which the right to exercise such warrants will commence and the date on which such right shall expire;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">&#8226;</TD><TD>any
provisions for adjustment of the number or amount of securities receivable upon exercise of the warrants or the exercise price of the
warrants;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">&#8226;</TD><TD>if
applicable, the minimum or maximum amount of such warrants that may be exercised at any one time;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">&#8226;</TD><TD>if
applicable, the designation and terms of the securities with which such warrants are issued and the number of such warrants issued with
each such security;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">&#8226;</TD><TD>if
applicable, the date on and after which such warrants and the related securities will be separately transferable;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">&#8226;</TD><TD>information
with respect to book-entry procedures, if any; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">&#8226;</TD><TD>any
other terms of such warrants, including terms, procedures and limitations relating to the exchange or exercise of such warrants.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">The prospectus supplement relating to any warrants
to purchase equity securities may also include, if applicable, a discussion of certain U.S. federal income tax and ERISA considerations.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Each warrant will entitle its holder to purchase the
number of ordinary shares or units at the exercise price set forth in, or calculable as set forth in, the applicable prospectus supplement.</P>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">After the close of business on the expiration date,
unexercised warrants will become void. We will specify the place or places where, and the manner in which, warrants may be exercised in
the applicable prospectus supplement.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Prior to the exercise of any warrants to purchase
ordinary shares or units, holders of the warrants will not have any of the rights as holders of the ordinary shares or units purchasable
upon exercise.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.55in">&nbsp;</P>


<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0"><B><A NAME="a_011"></A>DESCRIPTION OF UNITS WE MAY OFFER</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 45pt; margin: 0pt 0; background-color: white">We may issue units consisting
of a combination of two or more of any offered securities, at a single price or at a separate price for each security included in the
unit. The securities offered may be issued separately or may be evidenced by a separate unit certificate, which may or may not trade separately.
The terms and conditions governing the issuance of any units, including the form and content of any certificate evidencing the units,
will be described in detail in the prospectus supplement to be filed in connection with the offering of such units.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><A NAME="a_012"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.55in; margin: 0pt 0">We may sell the securities offered through this prospectus
(1) to or through underwriters or dealers, (2) directly to purchasers, including our affiliates, (3) through agents, or (4) through a
combination of any these methods. The securities may be distributed at a fixed price or prices, which may be changed, market prices prevailing
at the time of sale, prices related to the prevailing market prices, or negotiated prices. The prospectus supplement will include the
following information:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.55in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.55in">&#9679; &#9;the terms of the offering;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.55in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.55in; margin: 0pt 0">&#9679; &#9;the names of any underwriters or agents;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.55in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.55in; margin: 0pt 0">&#9679; &#9;the name or names of any managing underwriter
or underwriters;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.55in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.55in; margin: 0pt 0">&#9679;&#9; the purchase price of the securities;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.55in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.55in; margin: 0pt 0">&#9679; &#9;the net proceeds from the sale of the
securities;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.55in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.55in; margin: 0pt 0">&#9679;&#9; any delayed delivery arrangements;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.55in">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.55in">&#9679;
&#9;any underwriting discounts, commissions and other items constituting underwriters&rsquo; compensation;</P>



<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.55in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.55in; margin: 0pt 0">&#9679; &#9;any initial public offering price;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.55in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.55in; margin: 0pt 0">&#9679; &#9;any discounts or concessions allowed or
reallowed or paid to dealers; and</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.55in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.55in; margin: 0pt 0">&#9679; &#9;any commissions paid to agents.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.55in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>Sale Through Underwriters or Dealers</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">If underwriters are used in the sale of our securities,
the underwriters will acquire the securities for their own account, including through underwriting, purchase, security lending or repurchase
agreements with us. The underwriters may resell the securities from time to time in one or more transactions, including negotiated transactions.
Underwriters may sell the securities in order to facilitate transactions in any of our other securities (described in this prospectus
or otherwise), including other public or private transactions and short sales. Underwriters may offer securities to the public either
through underwriting syndicates represented by one or more managing underwriters or directly by one or more firms acting as underwriters.
Unless otherwise indicated in the prospectus supplement, the obligations of the underwriters to purchase the securities will be subject
to certain conditions, and the underwriters will be obligated to purchase all the offered securities if they purchase any of them. The
underwriters may change from time to time any initial public offering price and any discounts or concessions allowed or reallowed or paid
to dealers.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">If dealers are used in the sale of securities offered
through this prospectus, we will sell the securities to them as principals. They may then resell those securities to the public at varying
prices determined by the dealers at the time of resale. The prospectus supplement will include the names of the dealers and the terms
of the transaction.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">If 5% or more of the net proceeds of any offering of
our securities made under this prospectus will be received by a FINRA member participating in the offering or affiliates or associated
persons of such FINRA member, the offering will be conducted in accordance with FINRA Rule 5121.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">To comply with the securities laws of certain states,
if applicable, the securities offered by this prospectus will be offered and sold in those states only through registered or licensed
brokers or dealers.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Direct Sales and Sales Through Agents</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">We may sell the securities offered through this prospectus
directly. In this case, no underwriters, dealers or agents would be involved. The securities may also be sold through agents, legally
permitted to act as securities agents, designated from time to time. The prospectus supplement will name any agent involved in the offer
or sale of the offered securities and will describe any commissions payable to the agent. Unless otherwise indicated in the prospectus
supplement, any agent will agree to use its reasonable best efforts to solicit purchases for the period of its appointment.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">We may sell the securities directly to institutional
investors or others who may be deemed to be underwriters within the meaning of the Securities Act with respect to any sale of those securities.
The terms of any such sales will be described in the prospectus supplement.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Underwriter, Dealer or Agent Discounts and Commissions</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Underwriters, dealers or agents may receive compensation
in the form of discounts, concessions or commissions from us or our purchasers as their agents in connection with the sale of securities,
provided they are legally permitted to receive compensation for transactions in securities. These underwriters, dealers or agents may
be considered to be underwriters under the Securities Act. As a result, discounts, commissions, or profits on resale received by the underwriters,
dealers or agents may be treated as underwriting discounts and commissions. Each prospectus supplement will identify any such underwriter,
dealer or agent, and describe any compensation received by them from us. Any initial public offering price and any discounts or concessions
allowed or reallowed or paid to dealers may be changed from time to time.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The maximum commission or discount to be received by
any underwriter, dealer or agent will not be greater than eight percent (8%) of the maximum gross proceeds of the securities that may
be sold under this prospectus. In order to pay any commissions or discounts or other fees, the underwriter, dealer or agent will be required
to be registered with appropriate agencies and legally permitted to receive a commission, discount or fee in connection with the sale
of securities in all relevant jurisdictions.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>Indemnification</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">Agents, underwriters and dealers may be entitled to
indemnification by us against specified liabilities, including liabilities incurred under the Securities Act, or to contribution by us
to payments they may be required to make in respect of such liabilities. The prospectus supplement will describe the terms and conditions
of such indemnification or contribution. Some of the agents, underwriters or dealers, or their respective affiliates, may be customers
of, engage in transactions with or perform services for us in the ordinary course of business. We will describe in the prospectus supplement
naming the underwriter the nature of any such relationship.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Delayed Delivery Contracts</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">If the prospectus supplement indicates, we may authorize
agents, underwriters or dealers to solicit offers from certain types of institutions to purchase securities at the public offering price
under delayed delivery contracts. These contracts would provide for payment and delivery on a specified date in the future. The contracts
would be subject only to those conditions described in the prospectus supplement. The applicable prospectus supplement will describe the
commission payable for solicitation of those contracts.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Market Making, Stabilization and Other Transactions</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Unless the applicable prospectus supplement states
otherwise, each series of offered securities will be a new issue and will have no established trading market. We may elect to list any
series of offered securities on an exchange or in another trading medium. Any underwriters or other agents that we use in the sale of
offered securities may make a market in such securities, but may discontinue such market making at any time without notice. Therefore,
we cannot assure you that the securities will have a liquid trading market.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Any underwriter or dealer may also engage in stabilizing
transactions, syndicate covering transactions and penalty bids in accordance with Rule 104 under the Exchange Act. Stabilizing transactions
involve bids to purchase the underlying security in the open market for the purpose of pegging, fixing or maintaining the price of the
securities. Syndicate covering transactions involve purchases of the securities in the open market after the distribution has been completed
in order to cover syndicate short positions.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Penalty bids permit the underwriters and dealers to
reclaim a selling concession from a syndicate member when the securities originally sold by the syndicate member are purchased in a syndicate
covering transaction to cover syndicate short positions. Stabilizing transactions, syndicate covering transactions and penalty bids may
cause the price of the securities to be higher than it would be in the absence of the transactions. The underwriters or dealers may, if
they commence these transactions, discontinue them at any time.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Derivative Transactions and Hedging</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The underwriters, dealers or other agents may engage
in derivative transactions involving the securities. These derivatives may consist of short sale transactions and other hedging activities.
The underwriters, dealers or agents may acquire a long or short position in the securities, hold or resell securities acquired and purchase
options or futures on the securities and other derivative instruments with returns linked to or related to changes in the price of the
securities. In order to facilitate these derivative transactions, we may enter into security lending or repurchase agreements with the
underwriters or agents. The underwriters, dealers or agents may effect the derivative transactions through sales of the securities to
the public, including short sales, or by lending the securities in order to facilitate short sale transactions by others. The underwriters,
dealers or agents may also use the securities purchased or borrowed from us or others (or, in the case of derivatives, securities received
from us in settlement of those derivatives) to directly or indirectly settle sales of the securities or close out any related open borrowings
of the securities.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>General Information</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Agents, underwriters, and dealers may be entitled,
under agreements entered into with us, to indemnification by us against certain liabilities, including liabilities under the Securities
Act.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>Exchange Requirements</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">If the class of securities, or derivative securities
based on those securities, that is being sold are listed on an exchange, the company may be required to make an application to the exchange
for listing of additional securities, and the issuance may be subject to limitations set forth in the listing rules.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0"><B><A NAME="a_013"></A>CERTAIN UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The material United States Federal income tax consequences
relating to the purchase, ownership and disposition of any of the securities offered by this prospectus will be set forth in the applicable
prospectus supplement relating to the offering of those securities. Information about certain tax issues related to owning our securities
is set forth in our Annual Report on Form 20-F for the fiscal year ended March 31, 2020 and incorporated by reference herein, which will
be amended by subsequently filed Annual Reports on Form 20-F and any prospectus supplement that discusses such matters.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0"><B><A NAME="a_014"></A>BRITISH VIRGIN ISLANDS TAXATION</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The following is a discussion on certain British Virgin
Islands income tax consequences of an investment in our securities. The discussion is a general summary of present law, which is subject
to prospective and retroactive change. It is not intended as tax advice, does not consider any investor&rsquo;s particular circumstances,
and does not consider tax consequences other than those arising under British Virgin Islands law.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Under Existing British Virgin Islands Laws</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Government of the British Virgin Islands does not,
under existing legislation, impose any income, corporate or capital gains tax, estate duty, inheritance tax, gift tax or withholding tax
upon our Company or our security holders who are not tax resident in the British Virgin Islands.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Our company and all distributions, interest and other
amounts paid by our company to persons who are not tax resident in the British Virgin Islands will not be subject to any income, withholding
or capital gains taxes in the British Virgin Islands, with respect to the shares in our company owned by them and dividends received on
such shares, nor will they be subject to any estate or inheritance taxes in the British Virgin Islands.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">No estate, inheritance, succession or gift tax, rate,
duty, levy or other charge is payable by persons who are not tax resident in the British Virgin Islands with respect to any shares or
other securities of our company.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Except to the extent that we have any interest in
real property in the British Virgin Islands, all instruments relating to transactions in respect of the shares or other securities of
our company and all instruments relating to other transactions relating to the business of our company are exempt from the payment of
stamp duty in the British Virgin Islands.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">There are currently no withholding taxes or exchange
control regulations in the British Virgin Islands applicable to our company or our security holders.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0"><B><A NAME="a_015"></A>BVI DATA PROTECTION</B></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Data Protection Act, 2021 (the &ldquo;<B>BVI DPA</B>&rdquo;)
establishes a framework of rights and duties designed to safeguard individuals&rsquo; personal data, balanced against the need of public
authorities, businesses and organizations to collect and use personal data for lawful purposes. The BVI DPA is centred around seven data
protection principles (the General Principle, the Notice and Choice Principle, the Disclosure Principle, the Security Principle, the Retention
Principle, the Data Protection Principle and the Access Principle) which require that:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.2in">&bull;</TD><TD STYLE="text-align: justify">personal data must not be processed without consent unless specific conditions are met and must not be
transferred outside the British Virgin Islands, unless there is proof of adequate data protection safeguards or consent from the data
subject;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.2in">&bull;</TD><TD STYLE="text-align: justify">Where consent has been given to processing of personal data, the data subject may at any time withdraw
his or her consent;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.2in">&bull;</TD><TD STYLE="text-align: justify">a data controller must inform a data subject of specific matters, for instance the purposes for which
it is being collected and further processed;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.2in">&bull;</TD><TD STYLE="text-align: justify">personal data must not be disclosed for any purpose other than the purpose for which it was to be disclosed
at the time of collection or a purpose directly related thereto or to any party other than a third party of a class previously notified
to the data subject;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.2in">&bull;</TD><TD STYLE="text-align: justify">a data controller shall, when processing personal data, take practical steps to protect personal data
from loss, misuse, modification, unauthorized or accidental access or disclosure, alteration or destruction;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.2in">&bull;</TD><TD STYLE="text-align: justify">personal data must not be kept for longer than is necessary for the purpose;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.2in">&bull;</TD><TD STYLE="text-align: justify">personal data must be accurate, complete, not misleading and kept up to date; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.2in">&bull;</TD><TD STYLE="text-align: justify">a data subject must be given access to his or her own personal data and be able to correct that data where
it is inaccurate, incomplete, misleading or not up to date, except where a request for such access or correction is refused under the
BVI DPA.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The BVI DPA imposes specific obligations on data controllers,
including the duty to (i) apply the data protection principles; and (ii) respond in a timely fashion to requests from data subjects in
relation to their personal data.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The Information Commissioner is the regulator responsible
for the proper functioning and enforcement of the BVI DPA. Offences under the BVI DPA include:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.2in">&bull;</TD><TD STYLE="text-align: justify">processing sensitive personal data in contravention of the BVI DPA;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.2in">&bull;</TD><TD STYLE="text-align: justify">willfully obstructing the Information Commissioner or an authorized officer in the conduct of his or her
duties and functions;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.2in">&bull;</TD><TD STYLE="text-align: justify">willfully disclosing personal information in contravention of the BVI DPA; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.2in">&bull;</TD><TD STYLE="text-align: justify">collecting, storing or disposing of personal information in a manner that contravenes the BVI DPA.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Offences committed under the BVI DPA may result in
fines (up to US$500,000 in certain cases) or imprisonment. Further, a data subject who suffers damage or distress as a result of their
data being processed in contravention of the DPA may institute civil proceedings in the British Virgin Islands courts.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><A NAME="a_016"></A>TRANSFER AGENT</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The transfer agent for our ordinary shares is TSX
Trust Company, 100 Adelaide St W, Suite 301, Toronto, ON M5H  4H1 Canada, Tel: 416-361-0930.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The company&rsquo;s registered agent in the British
Virgin Islands is FH Corporate Services Ltd., Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, BVI.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><A NAME="a_017"></A>LEGAL MATTERS</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Certain legal matters in connection with the securities
offered hereby, including the validity of the securities, and British Virgin Islands law will be passed upon for us by Forbes Hare, Road
Town, Tortola, British Virgin Islands.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><A NAME="a_018"></A>EXPERTS</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">The consolidated financial statements of the Company,
appearing in its Form 20-F Annual Report filed with the SEC on August 14, 2024, for the fiscal years ended March 31, 2024 and 2023, have
been audited by Marcum LLP, an independent registered public accounting firm, as stated in its report appearing therein. The audited consolidated
financial statements are incorporated hereby by reference in reliance upon the report of such firm given upon its authority as experts
in accounting and auditing.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B><A NAME="a_019"></A>ENFORCEABILITY OF CIVIL LIABILITIES</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">We are incorporated in the British Virgin Islands.
There may be perceived disadvantages for investors that accompany incorporation in the British Virgin Islands, which may include the facts
that the British Virgin Islands has a less developed body of securities laws as compared to the United States providing significantly
less protection to investors.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">Our organizational documents do not contain provisions
requiring disputes be submitted to arbitration, including those arising under the securities laws of the United States, between us, our
officers, directors and shareholders. Therefore, actions in these controversies will have to be heard in formal court forums, which may
be more costly and less flexible, and laws, interpretations and precedent may or may not be consistent or available.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">An important part of our operations is conducted and
a significant portion of our assets is located outside the United States. Some of our directors and officers are nationals or residents
of jurisdictions other than the United States, and some or all of their assets are located outside the United States. As a result, it
may be difficult or impossible for a shareholder to bring an original action against us or those persons in a British Virgin Islands or
other court in the event that a shareholder believes that his or her rights have been infringed under the United States federal securities
laws or otherwise. It may also be difficult for a shareholder to enforce in United States courts judgments obtained in United States courts
based on the civil liability provisions of the United States federal securities laws against us and our officers and directors, some of
whom are not residents of the United States and whose assets are located outside of the United States. In addition, there is uncertainty
as to whether the courts of the British Virgin Islands would recognize or enforce judgments of United States courts against us or those
persons predicated upon the civil liability provisions of the securities laws of the United States or any state. There is no statutory
recognition in the British Virgin Islands of judgments obtained in the United States, although the courts of the British Virgin Islands
will generally recognize and enforce a non-penal judgment of a foreign court of competent jurisdiction without retrial on the merits.
It is uncertain whether British Virgin Islands courts would be competent to hear original actions brought in the British Virgin Islands
against us or those persons predicated upon the securities laws of the United States or any state.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">Our corporate affairs are governed by our memorandum
and articles and by the Companies Law and common law of the British Virgin Islands. The rights of shareholders to take legal action against
our directors and us, actions by minority shareholders and the fiduciary responsibilities of our directors to us under British Virgin
Islands law are to a large extent governed by the common law of the British Virgin Islands and the relevant company law, court procedures
and other relevant regulation. The common law of the British Virgin Islands is derived in part from comparatively limited judicial precedent
in the British Virgin Islands as well as from English common law, which has persuasive, but not binding, authority on a court in the British
Virgin Islands. The rights of our shareholders and the fiduciary responsibilities of our directors under British Virgin Islands law are
not as clearly established as they would be under statutes or judicial precedents in the United States. In particular, the British Virgin
Islands has no securities laws as compared to the United States, and provides less protection to investors in many instances. In addition,
British Virgin Islands companies may not have standing to initiate a shareholder derivative action before the federal courts of the United
States.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">As a result of all of the above, our shareholders may
have more difficulties in protecting their interests through actions against our management, directors or major shareholders than would
shareholders of a corporation incorporated and operating in a jurisdiction in the United States.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">Forbes Hare, our counsel as to British Virgin Islands
law, have advised us that there is uncertainty as to whether the courts of the British Virgin Islands would:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;recognize
or enforce judgments of United States courts obtained against us or our directors or officers predicated upon the civil liability provisions
of the securities laws of the United States or any state in the United States; or</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;entertain
original actions brought in each respective jurisdiction against us or our directors or officers predicated upon the securities laws of
the United States or any state in the United States.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 0.5in">Forbes Hare, has further advised us that the United
States and the British Virgin Islands do not have a treaty providing for reciprocal recognition and enforcement of judgments of United
States courts in civil and commercial matters and that a final judgment for the payment of money rendered by any federal or state court
in the United States based on civil liability, whether or not predicated solely upon the United States federal securities laws, would
not be automatically enforceable in the British Virgin Islands. We have also been advised that any final and conclusive monetary judgment
for a definite sum obtained against the company in United States federal or state courts would be treated by the courts of the British
Virgin Islands as a cause of action in itself and sued upon as a debt at common law so that no retrial of the issues would be necessary
provided that:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the United
States federal or state court had jurisdiction in the matter and the company either submitted to such jurisdiction or was resident or
carrying on business within such jurisdiction and was duly served with process;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the judgment
given by the United States federal or state court was not in respect of penalties, taxes, fines or similar fiscal or revenue obligations;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
judgment was not procured by fraud;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;recognition
or enforcement of the judgment in the British Virgin Islands would not be contrary to public policy; and</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the proceedings
pursuant to which judgment was obtained were not contrary to natural justice.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">A British Virgin Islands court may impose civil liability
on us or our directors or officers in a suit brought in the courts of the British Virgin Islands against us or these persons with respect
to a violation of United States federal securities laws, provided that the facts surrounding any violation constitute or give rise to
a cause of action under British Virgin Islands law.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; text-indent: 0.5in">We have appointed Andrea Park, the company Chief Financial
Officer, as our agent to receive service of process with respect to any action brought against us in the United States under the federal
securities laws of the United States.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">26</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"></P>













</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
